161 related articles for article (PubMed ID: 26033599)
1. Experimental Modeling of Proliferative Vitreoretinopathy. An Experimental Morphological Study.
Khoroshilova-Maslova IP; Leparskaya NL; Nabieva MM; Andreeva LD
Bull Exp Biol Med; 2015 May; 159(1):100-2. PubMed ID: 26033599
[TBL] [Abstract][Full Text] [Related]
2. [The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy].
Khoroshilova-Maslova IP; Leparskaya NL; Vorotelyak EA; Vasiliev AV
Vestn Oftalmol; 2017; 133(5):4-10. PubMed ID: 29165406
[TBL] [Abstract][Full Text] [Related]
3. [Experimental morphological study of posttraumatic proliferative vitreoretinopathy prevention by cell adhesion peptide Arg-Gly-Asp-Ser].
Khoroshilova-Maslova IP; Babizhaev MA; Kiseleva OA; Ilatovskaia LV
Vestn Oftalmol; 1997; 113(4):27-31. PubMed ID: 9381638
[TBL] [Abstract][Full Text] [Related]
4. Pathological vitreous causes cell line-derived (but not donor-derived) retinal pigment epithelial cells to display proliferative vitreoretinopathy-like features in culture.
Sharma M; Tiwari A; Sharma S; Bansal R; Gupta V; Gupta A; Luthra-Guptasarma M
Clin Exp Ophthalmol; 2014 Nov; 42(8):745-60. PubMed ID: 24612444
[TBL] [Abstract][Full Text] [Related]
5. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration.
Oberstein SY; Byun J; Herrera D; Chapin EA; Fisher SK; Lewis GP
Mol Vis; 2011; 17():1794-805. PubMed ID: 21750605
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
[TBL] [Abstract][Full Text] [Related]
7. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
Liou GI; Pakalnis VA; Matragoon S; Samuel S; Behzadian MA; Baker J; Khalil IE; Roon P; Caldwell RB; Hunt RC; Marcus DM
Mol Vis; 2002 Dec; 8():494-501. PubMed ID: 12500176
[TBL] [Abstract][Full Text] [Related]
8. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation.
Snead DR; James S; Snead MP
Eye (Lond); 2008 Oct; 22(10):1310-7. PubMed ID: 18344963
[TBL] [Abstract][Full Text] [Related]
9. Role of retinal pigment epithelial cell β-catenin signaling in experimental proliferative vitreoretinopathy.
Umazume K; Tsukahara R; Liu L; Fernandez de Castro JP; McDonald K; Kaplan HJ; Tamiya S
Am J Pathol; 2014 May; 184(5):1419-28. PubMed ID: 24656918
[TBL] [Abstract][Full Text] [Related]
10. Proliferative vitreoretinopathy in the Swine-a new model.
Umazume K; Barak Y; McDonald K; Liu L; Kaplan HJ; Tamiya S
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4910-6. PubMed ID: 22729438
[TBL] [Abstract][Full Text] [Related]
11. P38 inhibition reverses TGFβ1 and TNFα-induced contraction in a model of proliferative vitreoretinopathy.
Schiff L; Boles NC; Fernandes M; Nachmani B; Gentile R; Blenkinsop TA
Commun Biol; 2019; 2():162. PubMed ID: 31069271
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy.
Kuo HK; Chen YH; Kuo YH; Ke MC; Tseng YC; Wu PC
Curr Eye Res; 2018 Mar; 43(3):333-339. PubMed ID: 29182404
[TBL] [Abstract][Full Text] [Related]
13. [Stages of cell proliferation in an experimental model of vitreoretinal proliferation following injection of platelet-rich plasma].
Pisella PJ; Baudouin C
J Fr Ophtalmol; 1996; 19(10):576-84. PubMed ID: 8959097
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.
Rubsamen PE; Cousins SW
Retina; 1997; 17(1):44-50. PubMed ID: 9051842
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy.
Ishikawa K; He S; Terasaki H; Nazari H; Zhang H; Spee C; Kannan R; Hinton DR
Sci Rep; 2015 Nov; 5():16386. PubMed ID: 26552368
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
17. Is vasoproliferative tumour (reactive retinal glioangiosis) part of the spectrum of proliferative vitreoretinopathy?
Hiscott P; Mudhar H
Eye (Lond); 2009 Sep; 23(9):1851-8. PubMed ID: 19011602
[TBL] [Abstract][Full Text] [Related]
18. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
Huang L; Xu Y; Yu W; Li Y; Chu L; Dong J; Li X
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3193-204. PubMed ID: 20071679
[TBL] [Abstract][Full Text] [Related]
19. [Vitreoretinal interface: pathophysiological, morphological and functional aspects].
Haritoglou C
Ophthalmologe; 2015 Jan; 112(1):8-9. PubMed ID: 25583418
[No Abstract] [Full Text] [Related]
20. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.
Lei H; Velez G; Cui J; Samad A; Maberley D; Matsubara J; Kazlauskas A
Am J Pathol; 2010 Jul; 177(1):132-40. PubMed ID: 20489144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
